Showing results (41-50 of 141) with videos related to
Sort By:
Pageof 15
American Journal of Clinical Oncology|October 1, 2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981Scott T Tagawa, Matthew I Milowsky, Stephanie Jeske, et al.Journal of Clinical Pharmacology|May 20, 2009
Phase I study of oral lenalidomide in patients with refractory metastatic cancerWilliam L Dahut, Jeanny B Aragon-Ching, Sukyung Woo, et al.Archives of Dermatology|June 19, 2008
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnibDavid S Hong, Srini B Reddy, Victor G Prieto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trialJudith E Karp, Douglas D Ross, Weidong Yang, et al.Blood|August 30, 2003
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 settingRazelle Kurzrock, Hagop M Kantarjian, Jorge E Cortes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemiaJudith E Karp, B Douglas Smith, Mark J Levis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancerJared A Gollob, W Kimryn Rathmell, Tina M Richmond, et al.Pediatric Blood & Cancer|September 23, 2010
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology GroupBrigitte C Widemann, Robert J Arceci, Nalini Jayaprakash, et al.Investigational New Drugs|March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumSrikala S Sridhar, Eric Winquist, Andrea Eisen, et al.Cancer|October 29, 2009
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysisEric Jonasch, Paul Corn, Lance C Pagliaro, et al.Pageof 15